United Therapeutics Corporation

It earns most of its revenue from one-time sales of a small number of approved drugs, recognized when distributors take control of the product, rather than from subscriptions or usage-based fees; a smaller service line earns fees for assessing donor lungs case by case.

Its established medicines scale by adding prescribers and patients within existing regulatory approvals; revenue and profit have grown in each recent year, with margins staying elevated even as capital spending runs ahead of depreciation, a combination consistent with a still-growing physical asset base. Its newer organ-manufacturing programs scale differently: each increment of future capacity requires constructing a new physical facility and clearing regulatory review, so growth there is paced by construction and approval timelines rather than by prescriber demand alone.

It depends on a small number of single-source contract manufacturers for specific products and devices, such as MannKind for one inhaled therapy and DEKA for its drug-delivery pumps, and it discloses that some products have no FDA-approved backup manufacturing site. It also depends on basic utility inputs like municipal water and electricity at its own plants, on an international supply chain for lower-tier materials, and on regulatory approval together with government and private insurance reimbursement in order for its products to generate revenue.

Its direct customers are a small number of specialty pharmaceutical distributors that hold inventory of its products and route them onward to pharmacies, prescribers, and patients who depend on continued access to the specific drug they have been prescribed. Transplant centers separately depend on its organ-assessment service to help surgeons decide whether a donor lung is suitable for transplant, and international sales depend on separate distributor relationships in each market.

The company itself states that one of its oral therapies is the only FDA-approved product of its kind that can be titrated without an upper dose limit, and that its centralized donor-lung assessment service is the only one of its kind commercially available in its home market. These are the company's own claims about specific products and services, and CompanyGraph has not independently verified them or assessed whether competitors could replicate them. Separately, earning revenue only after a product clears regulatory approval, the operating model this company runs under, is shared by a sizable group of companies in CompanyGraph's data, so that broader model is not itself unusual even where individual products are claimed to be.

The company's own filings describe its growth as limited by regulatory and clinical outcomes, reimbursement and competitive pressure, patent challenges, and manufacturing capacity, including long lead times for specialized equipment and difficulty staffing manufacturing sites. It has also disclosed a case where limited manufacturing batch capacity for one product constrained supply enough to delay new patients starting treatment in an overseas market, showing that physical production capacity can act as an active limit alongside regulatory clearance. More broadly, companies whose products must clear a similar regulatory approval gate before sale tend to be bound by that gate as a general pattern; this is a comparison CompanyGraph draws against the wider group, not something measured specifically for this company.

The company itself names heavy reliance on sales of a small number of approved drugs as the risk it discloses first, ahead of competition, reimbursement and pricing pressure, and its manufacturing strategy. It also discloses dependence on a small number of domestic distributors for most of the revenue from its core drug class, on manufacturers that are the sole approved source for specific products with no backup manufacturing site in some cases, and on the outcome of ongoing patent and contract litigation and possible regulatory enforcement action over its drug-pricing program.

Its own filings name dependence on the FDA and equivalent foreign regulators for approval, and on reimbursement decisions by government health programs and private insurers for its products to be affordable to patients. They also disclose ongoing patent and contract litigation involving named competitors and payers, and tariff and trade exposure affecting raw materials, consumables, and construction materials sourced in part from overseas markets.